Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission

INTRODUCTION: Mutations in leucine‐rich repeat kinase 2 (LRRK2) are the most prevalent cause of familial and sporadic Parkinson's disease (PD). Because most pathogenic LRRK2 mutations result in enhanced kinase activity, it suggests that LRRK2 inhibitors may serve as a potential treatment for PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Qi, Zhi, Lian‐Teng, Li, Xian‐Ting, Yue, Zhen‐Yu, Li, Guo‐Zhong, Zhang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248597/
https://www.ncbi.nlm.nih.gov/pubmed/27943591
http://dx.doi.org/10.1111/cns.12660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248597/
https://www.ncbi.nlm.nih.gov/pubmed/27943591
http://dx.doi.org/10.1111/cns.12660

Ejemplares similares